肝硬化门脉高压症并发血栓形成机制和治疗研究进展*

doi:10.3969/j.issn.1672-5069.2019.06.039

Abstract

Abstract: The portal thrombosis in cirrhotic patients with portal hypertension is a difficult problem in clinical practice. In this review,we made a summary about studies related on its pathological mechanism and treatment of portal vein thrombosis in patients with portal hypertension. At present,the mechanisms are mainly involving the activities of hepatic stellate cells,endothelial cell functions and the imbalance between pro-coagulation and anticoagulation. For the treatment,it consists of anticoagulant therapy,such as low molecular weight heparin,reducing portal vein pressure,like the combination of β-blockers with other medicines,simvastatin,rifaximin and probiotics,for instance,the increase of eNOS phosphorylation,and antioxidant therapy for mitochondria.

Key words: Portal hypertension, Portal thrombosis, Mechanism, Treatment

Zhang Rui, Wang Jian, Chen Shiyao.. Mechanism of portal vein thrombosis in cirrhotic patients with portal hypertension and the treatment[J]. Journal of Practical Hepatology, 2019, 22(6): 930-933.

References

[1] Loffredo L,Pastori D,Farcomeni A,et al.Effects of anticoagulants in patients with cirrhosis and portal vein thrombosis:a systematic review and Meta-analysis. Gastroenterology,2017,153(2):480-487.
[2] Fernandez M.Molecular pathophysiology of portal hypertension. Hepatology,2015,61(4):1406-1415.
[3] Gaca MD,Zhou X,Benyon RC.Regulation of hepatic stellate cell proliferation and collagen synthesis by proteinase-activated receptors. J Hepatol,2002,36(3):362-369.
[4] Rockey DC,Chung JJ.Reduced nitric oxide production by endothelial cells in cirrhotic rat liver:endothelial dysfunction in portal hypertension. Gastroenterology,1998,114(2):344-351.
[5] Zeng XQ,Li N,Pan DY,et al.Kruppel-like factor 2 inhibit the angiogenesis of cultured human liver sinusoidal endothelial cells through the ERK1/2 signaling pathway.Biochem Biophys Res Commun,2015,464(4):1241-1247.
[6] Tripathi D,Hayes PC.Beta-blockers in portal hypertension: new developments and controversies. Liver Int,2014,34:655-667.
[7] Reiberger T,Ferlitsch A,Payer BA,et al.Non-selective betabl-ocker therapy decreases intestinal permeability and serum levels of LBP and IL-6 in patients with cirrhosis.J Hepatol,2013,58:911-921.
[8] Kim JH,Kim JM,Cho YZ,et al.Effects of candesartan and propranolol combination therapy versus propranolol monotherapy in reducing portal hypertension. Clin Mol Hepatol,2014,20:376-383.
[9] Sersté T,Melot C,Francoz C,et al.Deleterious effects of beta-blockers on survival in patients with cirrhosis and refractory ascites. Hepatology,2010,52:1017-1022.
[10] Shafiei MS,Lui S,Rockey DC.Integrin-linked kinase regulates endothelial cell nitric oxide synthase expression in hepatic sinusoidal endothelial cells. Liver Int,2015,35(4):1213-1221.
[11] Schwabl P,Hambruch E,Seeland BA,et al.The FXR agonist PX20606 ameliorates portal hypertension by targeting vascular remodelling and sinusoidal dysfunction.J Hepatol,2017,66(4):724-733.
[12] Vilaseca M,García-Calderó H,Lafoz E,et al.Mitochondria-targeted antioxidant mitoquinone deactivates human and rat hepatic stellate cells and reduces portal hypertension in cirrhotic rats. Liver Int,2017,37(7):1002-1012.
[13] Zheng L,Qin J,Sun L,et al.Intrahepatic upregulation of MRTF-A signaling contributes to increased hepatic vascular resistance in cirrhotic rats with portal hypertension. Clin Res Hepatol Gastroenterol,2017,41(3):303-310.
[14] Trebicka J,Hennenberg M,Laleman W,et al.Atorvastatin lowers portal pressure in cirrhotic rats by inhibition of RhoA/Rho-kinase and activation of endothelial nitric oxide synthase. Hepatology,2007,46(1):242-253.
[15] Matei V,Rodriguez-Vilarrupla A,Deulofeu R,et al.Three-day tetrahydrobiopterin therapy increases in vivo hepatic NOS activity and reduces portal pressure in CCl₄ cirrhotic rats. J Hepatol,2008,49:192-197.
[16] Klein S,Rick J,Lehmann J,et al.Janus-kinase-2 relates directly to portal hypertension and to complications in rodent and human cirrhosis. Gut,2017,66(1):145-155.
[17] Rosado E,Rodriguez-Vilarrupla A,Gracia-Sancho J,et al.Terutr-oban,a TP-receptor antagonist,reduces portal pressure in cirrhotic rats. Hepatology,2013,58:1424-1435.
[18] Abraldes JG,Albillos A,Banares R,et al.Simvastatin lowers portal pressure in patients with cirrhosis and portal hypertension:a randomized controlled trial. Gastroenterology,2009,136:1651-1658.
[19] Lim YL,Kim MY,Jang YO,et al.Rifaximin and propranolol combination therapy is more effective than propranolol monoth-erapy for the reduction of portal pressure:an open randomized controlled pilot study.Gut Liver,2017,11(5):702-710.
[20] Gupta N,Kumar A,Sharma P,et al.Effects of the adjunctive probiotic VSL#3 on portal haemodynamics in patients with cirrhosis and large varices:a randomized trial. Liver Int,2013,33(8):1148-1157.
[21] Manzano-Robleda Mdel C,Barranco-Fragoso B,Uribe M,et al. Portal vein thrombosis:what is new Ann Hepatol,2015,14(1):20-27.
[22] Amitrano L,Guardascione MA,Brancaccio V,et al.Risk factors and clinical presentation of portal vein thrombosis in patients with liver cirrhosis. J Hepatol,2004,40:736-741.
[23] DeLeve LD,Valla DC,Garcia-Tsao G. Vascular disorders of the liver. Hepatology,2009,49(5):1729-1964.
[24] Plessier A,Darwish-Murad S,Hernandez-Guerra M,et al.Acute portal vein thrombosis unrelated to cirrhosis:a prospective multicenter follow-up study. Hepatology,2010,51(1):210-218.
[25] Condat B,Pessione F,Helene Denninger M,et al.Recent portal or mesenteric venous thrombosis:increased recognition and frequent recanalization on anticoagulant therapy. Hepatology,2000,32(3):466-470.
[26] Intagliata NM,Northup PG.Anticoagulant therapy in patients with cirrhosis. Semin Thromb Hemost,2015,41(5):514-519.
[27] Vilaseca M,García-Calderó H,Lafoz E,et al.The anticoagulant rivaroxaban lowers portal hypertension in cirrhotic rats mainly by deactivating hepatic stellate cells. Hepatology,2017,65(6):2031-2044.
[28] Cerini F,Vilaseca M,Lafoz E,et al.Enoxaparin reduces hepatic vascular resistance and portal pressure in cirrhotic rats. J Hepatol,2016,64(4):834-842.
[29] Rossi J,Rouleau L,Tardif JC,et al.Effect of simvastatin on kruppel-like factor 2,endothelial nitric oxide synthase and thrombomodulin expression in endothelial cells under shear stress.Life Sci,2010,87(3-4):92-99.
[30] Pathak R,Shao L,Chafekar SM,et al.IKKβ regulates endothelial thrombomodulin in a Klf2-dependent manner.J Thromb Haemost,2014,12(9):1533-1544.
[31] Xu M,Xue W,Ma Z,et al.Resveratrol reduces the incidence of portal vein system thrombosis after splenectomy in a rat fibrosis model. Oxid Med Cell Longev,2016,7453849.
[32] Khatri A,Kanaparthy NS,Selvaraj BJ,et al.Primary Klebsiella pneumoniae osteomyelitis with bacteremia and sepsis in a patient with cirrhosis. Case Rep Infect Dis,2018,2018:3183805.
[33] Chung JW,Kim GH,Lee JH,et al.Safety,efficacy,and response predictors of anticoagulation for the treatment of nonmalignant portal-vein thrombosis in patients with cirrhosis:a propensity score matching analysis. Clin Mol Hepatol,2014,20(4):384-391.
[34] Villa E,Cammà C,Marietta M,et al.Enoxaparin prevents portal vein thrombosis and liver decompensation in patients with advanced cirrhosis. Gastroenterology,2012,143(5):1253-1260.

Mechanism of portal vein thrombosis in cirrhotic patients with portal hypertension and the treatment

PDF (PC)

Knowledge

Abstract

Cite this article

share this article

References

Related Articles 15

Recommended Articles

Metrics

Comments

[1]	Zhuang Ying, Lin Zhihui.. Clinical manifestations and diagnosis of portal vein thrombosis [J]. Journal of Practical Hepatology, 2019, 22(6): 765-767.
[2]	Pan Meimin, Li Wenjuan, Jiang Fangqing, et al.. Changes of serum IL-17A,fibroblast growth factor and IL-7 levels in patients with hepatitis C virus infection [J]. Journal of Practical Hepatology, 2019, 22(6): 840-843.
[3]	Liang Jubo, Miao Qi, Ma Xiong.. Diagnosis and treatment of cholangiocytic cholestasis [J]. Journal of Practical Hepatology, 2019, 22(6): 941-943.
[4]	Xiao Han, Wang Li. Mechanisms of thrombocytopenia in liver cirrhosis [J]. JOURNAL OF PRACTICAL HEPATOLOGY, 2019, 22(4): 462-465.
[5]	Zhang Yunfeng, Wei Ailin, Huang Jin, et al. Effect of modified Sugiura’s operation on portal hemodynamics in cirrhotic patients with portal hypertension [J]. JOURNAL OF PRACTICAL HEPATOLOGY, 2019, 22(4): 553-556.
[6]	Wang Wensheng, Chen Dongfeng, Wen Liangzhi. Highlights in portal hypertensive gastropathy [J]. JOURNAL OF PRACTICAL HEPATOLOGY, 2019, 22(4): 601-604.
[7]	Gao Zhiliang, Zhu Xiang. How to achieve the clinical cure of hepatitis B [J]. JOURNAL OF PRACTICAL HEPATOLOGY, 2019, 22(3): 305-308.
[8]	Wang Xiaoxiao, Chen Xinyue. Therapeutic strategy for serum HBsAg clearance in suitable population of chronic hepatitis B [J]. JOURNAL OF PRACTICAL HEPATOLOGY, 2019, 22(3): 309-312.
[9]	. Consensus on clinical application of hepatic venous pressure gradient in China (2018) [J]. JOURNAL OF PRACTICAL HEPATOLOGY, 2019, 22(3): 321-332.
[10]	Liu Li，Li Junyi，Du Yingrong. Efficacy and safety of sofosbuvir/daclatasvir in the treatment of patients with chronic hepatitis C and hepatitis C cirrhosis:An real-world study [J]. JOURNAL OF PRACTICAL HEPATOLOGY, 2019, 22(3): 361-364.
[11]	Guideline for diagnosis, treatment of liver failure. [J]. JOURNAL OF PRACTICAL HEPATOLOGY, 2019, 22(2): 164-171.
[12]	Chen Junbang, Li Jian, Liang Jundi, Quan Yi, Li Guangqing, Yang Kai. Application of transjugular intrahepatic portosystemic shunt in the treatment of cirrhotics with portal hypertension [J]. JOURNAL OF PRACTICAL HEPATOLOGY, 2019, 22(2): 228-231.
[13]	Zhao Xiaofei, Lin Dongdong, Li Ning, Zang Yunjin, Guo Qingliang, Wu Juanshan. Application of warfarin in dealing with portal vein thrombosis in patients with liver cirrhosis after splenectomy and devascularization [J]. JOURNAL OF PRACTICAL HEPATOLOGY, 2019, 22(2): 240-243.
[14]	Zhong Yan, Su Shuting, Mi Yuqiang.. Treatment of patients with nonalcoholic fatty liver disease [J]. JOURNAL OF PRACTICAL HEPATOLOGY, 2019, 22(1): 145-148.
[15]	Pu Yonglan, Chen Yuanwen, Fan Jiangao.. Gluten intestinal disease and nonalcoholic fatty liver: One case report [J]. JOURNAL OF PRACTICAL HEPATOLOGY, 2018, 21(6): 981-982.